Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

Fig. 5

Percentage of ACR20/50/70 and DAS28-CRP remission (≤ 2.6) by study visit (PPS). ACR, American College of Rheumatology; ACR20, ≥ 20% improvement; ACR50, ≥ 50% improvement; ACR70, ≥ 70% improvement; DAS28-CRP, 28-joint Disease Activity Score, C-reactive protein version; PBO, placebo; PPS, per-protocol set. p value of less than 0.05 is shown by an asterisk

Back to article page
\